New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
News|Articles|June 30, 2026
- Dermatology Times, June 2026 (Vol. 47. No. 06)
- Volume 47
- Issue 06
Dermatology Times June 2026 Print Recap
Author(s)Marie Bosslett, Assistant Editor
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Advertisement
Advertisement
The June issue of Dermatology Times includes a collection of thought-provoking articles and topics as we examine emerging evidence for ruxolitinib cream in hidradenitis suppurativa, explore the exciting update in US sunscreen formulations, review the Sun Bus’ community impact, and more.
Related to this article
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Advertisement
Advertisement